Entrada Therapeutics is advancing a pipeline of intracellular therapeutics based on its proprietary Endosomal Escape Vehicle platform. The EEV technology is designed to transport large therapeutic molecules, including oligonucleotides and proteins, across cell membranes to reach intracellular targets. Current development programs target neuromuscular diseases, inherited retinal diseases as well as metabolic conditions.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 20.6 | — | -17.4 | — |
| Q2 2025 | 1.9 | — | -43.1 | — |
| Q3 2025 | 1.6 | — | -44.1 | — |
| Q4 2025 | 1.3 | — | -39.2 | — |
| Q1 2026 | 0.9 | -95.7% | -39.7 | — |
| Q2 2026 | 0.9 | -54% | -42.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Expensify, Inc. (EXFY), OP Bancorp (OPBK), Aeluma, Inc. (ALMU), Soluna Holdings, Inc. (SLNH), Yarrow Bioscience, Inc. (YARW), Canaan Inc. (CAN)